KR20100108390A - ＪＡＫ２ 억제제로서 유용한 피라졸로［１，５－ａ］피리미딘 - Google Patents

ＪＡＫ２ 억제제로서 유용한 피라졸로［１，５－ａ］피리미딘 Download PDF

Info

Publication number
KR20100108390A
KR20100108390A KR1020107015961A KR20107015961A KR20100108390A KR 20100108390 A KR20100108390 A KR 20100108390A KR 1020107015961 A KR1020107015961 A KR 1020107015961A KR 20107015961 A KR20107015961 A KR 20107015961A KR 20100108390 A KR20100108390 A KR 20100108390A
Authority
KR
South Korea
Prior art keywords
aliphatic
ring
compound
membered
nhc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020107015961A
Other languages
English (en)
Korean (ko)
Inventor
마크 레데보어
미쉘 스튜어트
데이비드 메서스미스
존 더피
가브리엘 마르티네스-보테야
존 컴
화이 가오
프란세스코 살리투로
발레리 마론
알버트 피어스
Original Assignee
버텍스 파마슈티칼스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 버텍스 파마슈티칼스 인코포레이티드 filed Critical 버텍스 파마슈티칼스 인코포레이티드
Publication of KR20100108390A publication Critical patent/KR20100108390A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020107015961A 2007-12-19 2008-12-18 ＪＡＫ２ 억제제로서 유용한 피라졸로［１，５－ａ］피리미딘 Withdrawn KR20100108390A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1482407P 2007-12-19 2007-12-19
US61/014,824 2007-12-19

Publications (1)

Publication Number Publication Date
KR20100108390A true KR20100108390A (ko) 2010-10-06

Family

ID=40431839

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107015961A Withdrawn KR20100108390A (ko) 2007-12-19 2008-12-18 ＪＡＫ２ 억제제로서 유용한 피라졸로［１，５－ａ］피리미딘

Country Status (13)

Country Link
US (1) US8937064B2 (enExample)
EP (1) EP2252618A1 (enExample)
JP (1) JP5587206B2 (enExample)
KR (1) KR20100108390A (enExample)
CN (1) CN101932583A (enExample)
AU (1) AU2008343173A1 (enExample)
CA (1) CA2709710A1 (enExample)
IL (1) IL206466A0 (enExample)
MX (1) MX2010006748A (enExample)
NZ (1) NZ586662A (enExample)
RU (1) RU2010129928A (enExample)
WO (1) WO2009085913A1 (enExample)
ZA (1) ZA201004368B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR077999A1 (es) * 2009-09-02 2011-10-05 Vifor Int Ag Antagonistas de pirimidin y triazin-hepcidina
EP2338888A1 (en) * 2009-12-24 2011-06-29 Almirall, S.A. Imidazopyridine derivatives as JAK inhibitors
UY33213A (es) * 2010-02-18 2011-09-30 Almirall Sa Derivados de pirazol como inhibidores de jak
WO2012044561A2 (en) * 2010-09-30 2012-04-05 Merck Sharp & Dohme Corp. 2-alkoxy pyrimidine pde10 inhibitors
EP2463289A1 (en) 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
EP3409278B8 (en) 2011-07-21 2020-11-04 Sumitomo Dainippon Pharma Oncology, Inc. Heterocyclic protein kinase inhibitors
EP2554544A1 (en) 2011-08-01 2013-02-06 Almirall, S.A. Pyridin-2(1h)-one derivatives as jak inhibitors
US9089574B2 (en) 2011-11-30 2015-07-28 Emory University Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
CN102887858B (zh) * 2012-09-07 2014-11-19 苏州康润医药有限公司 3-氯-5-氨基-1h-吡唑-4-甲酸乙酯的合成方法
CN103073549A (zh) * 2012-09-07 2013-05-01 苏州康润医药有限公司 3-溴吡唑啉[1,5-α]吡嘧啶-2-甲酸的合成工艺
BR112015012454B1 (pt) 2012-12-07 2022-07-05 Vertex Pharmaceuticals Incorporated Compostos inibidores de atr quinase, seu uso e composição farmacêutica compreendendo os mesmos
ES2768678T3 (es) * 2013-12-06 2020-06-23 Vertex Pharma Compuesto de 2-amino-6-fluoro-N-[5-fluoro-piridin-3-il]pirazolo[1,5-a]pirimidin-3-carboxamida útil como inhibidor de la ATR quinasa, su preparación, diferentes formas sólidas y derivados radiomarcados de las mismas
WO2017013270A1 (en) 2015-07-23 2017-01-26 Universite De Strasbourg Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy
KR102678021B1 (ko) 2015-09-30 2024-06-26 버텍스 파마슈티칼스 인코포레이티드 Dna 손상제와 병용되는, atr 저해제를 포함하는 암 치료용 약제학적 조성물
US20210113562A1 (en) 2018-04-13 2021-04-22 Sumitomo Dainippon Pharma Oncology, Inc. Pim kinase inhibitors for treatment of myeloproliferative neoplasms and fibrosis associated with cancer
CA3127502A1 (en) 2019-02-12 2020-08-20 Sumitomo Dainippon Pharma Oncology, Inc. Formulations comprising heterocyclic protein kinase inhibitors
CN114761013A (zh) 2019-09-27 2022-07-15 迪斯克医药公司 治疗骨髓纤维化和相关病症的方法
KR20230012539A (ko) 2020-05-13 2023-01-26 디스크 메디슨, 인크. 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
EP4598539A2 (en) * 2022-10-04 2025-08-13 Children's Hospital Medical Center Multi-cyclic irak and flt3 inhibiting compounds and uses thereof
EP4611753A1 (en) 2022-10-31 2025-09-10 Sumitomo Pharma America, Inc. Pim1 inhibitor for treating myeloproliferative neoplasms

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
CZ68199A3 (cs) 1996-08-28 1999-11-17 Pfizer Inc. 6,5-Heterobicyklické deriváty, farmaceutická kompozice na jejich bázi a způsob léčení chorob
CA2291709A1 (en) 1997-05-30 1998-12-03 Merck & Co., Inc. Novel angiogenesis inhibitors
US6245759B1 (en) 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
US7713989B2 (en) * 2000-04-27 2010-05-11 Dow Robert L Glucocorticoid receptor modulators
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
CN1319968C (zh) 2002-08-02 2007-06-06 沃泰克斯药物股份有限公司 用作gsk－3的抑制剂的吡唑组合物
WO2004052315A2 (en) 2002-12-11 2004-06-24 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2004058749A1 (en) 2002-12-18 2004-07-15 Vertex Pharmaceuticals Incorporated Benzisoxazole derivatives useful as inhibitors of protein kinases
KR101164541B1 (ko) * 2004-01-12 2012-07-10 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 선택적 키나제 저해제
PT1730146E (pt) * 2004-03-30 2011-07-11 Vertex Pharma Azaindoles úteis como inibidores de jak e outras proteínas quinases
GB0519957D0 (en) 2005-09-30 2005-11-09 Sb Pharmco Inc Chemical compound
KR20070090172A (ko) 2004-11-04 2007-09-05 버텍스 파마슈티칼스 인코포레이티드 단백질 키나아제의 억제제로서 유용한피라졸로[1,5-ａ]피리미딘
WO2007017678A1 (en) 2005-08-09 2007-02-15 Eirx Therapeutics Limited Pyrazolo[1,5-a] pyrimidine compounds and pharmaceutical compositions containing them
NZ567133A (en) * 2005-09-30 2011-07-29 Vertex Pharma Deazapurines useful as inhibitors of janus kinases
US8513276B2 (en) * 2006-12-22 2013-08-20 Astex Therapeutics Limited Imidazo[1,2-a]pyridine compounds for use in treating cancer
KR20090120510A (ko) 2007-03-09 2009-11-24 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제 억제제로서 유용한 아미노피리미딘
AU2008282156B2 (en) * 2007-07-31 2014-07-17 Vertex Pharmaceuticals Incorporated Process for preparing 5-fluoro-1H-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof

Also Published As

Publication number Publication date
IL206466A0 (en) 2010-12-30
AU2008343173A1 (en) 2009-07-09
MX2010006748A (es) 2010-08-18
CA2709710A1 (en) 2009-07-09
EP2252618A1 (en) 2010-11-24
US8937064B2 (en) 2015-01-20
WO2009085913A1 (en) 2009-07-09
ZA201004368B (en) 2013-01-30
NZ586662A (en) 2012-08-31
JP5587206B2 (ja) 2014-09-10
RU2010129928A (ru) 2012-01-27
CN101932583A (zh) 2010-12-29
JP2011507881A (ja) 2011-03-10
US20110118255A1 (en) 2011-05-19

Similar Documents

Publication Publication Date Title
KR20100108390A (ko) ＪＡＫ２ 억제제로서 유용한 피라졸로［１，５－ａ］피리미딘
EP1931674B1 (en) Deazapurines useful as inhibitors of janus kinases
RU2435769C2 (ru) Пирролопиридины, полезные в качестве ингибиторов протеинкиназы
JP5144532B2 (ja) ｃ−Ｍｅｔ阻害剤及び用法
JP5389785B2 (ja) キナーゼ阻害剤として有用なチアゾールおよびピラゾール
EP2001884A1 (en) Deazapurines useful as inhibitors of janus kinases
JP5572087B2 (ja) キナーゼ阻害として有用なアミノピリミジン
EP1448564A2 (en) Substituted indolizine-like compounds and methods of use
JP2015007076A (ja) タンパク質キナーゼ阻害剤
JP2010508363A (ja) ヤヌスキナーゼの阻害剤として有用な三環系ヘテロアリール化合物
CA2681516A1 (en) Compounds useful as inhibitors of janus kinases
JP2010519174A (ja) ｃ−Ｍｅｔの複素環阻害薬およびその使用方法
HK1147093A (en) Pyrazolo [1,5-a] pyrimidines useful as jak2 inhibitors
MX2008004335A (en) Deazapurines useful as inhibitors of janus kinases
HK1142312A (en) Deazapurines useful as inhibitors of janus kinases

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20100716

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid